ROPINIROLE VERSUS LEVODOPA: BETTER CLINICAL BENEFITS IN PARKINSON’S DISEASE

Nahid Rao, Reenoo Jauhari, Pallavi Godiyal, Vaishali Sati, A. Babbar
{"title":"ROPINIROLE VERSUS LEVODOPA: BETTER CLINICAL BENEFITS IN PARKINSON’S DISEASE","authors":"Nahid Rao, Reenoo Jauhari, Pallavi Godiyal, Vaishali Sati, A. Babbar","doi":"10.31069/japsr.v5i3.02","DOIUrl":null,"url":null,"abstract":"Parkinson’s disease is a progressive, neurodegenerative disorder of the extrapyramidal nervous system affecting the mobility and control of the skeletal muscular system. Although PD can develop at any age, it begins most commonly in older adults, with a peak age at the onset of around 60 years. Levodopa and dopamine agonists such as ropinirole are used in Parkinson’s treatment. This complete literature search was done using Google Scholar and PubMed. This review is to compare the safety and efficacy of ropinirole with that of Levodopa.","PeriodicalId":13749,"journal":{"name":"INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31069/japsr.v5i3.02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Parkinson’s disease is a progressive, neurodegenerative disorder of the extrapyramidal nervous system affecting the mobility and control of the skeletal muscular system. Although PD can develop at any age, it begins most commonly in older adults, with a peak age at the onset of around 60 years. Levodopa and dopamine agonists such as ropinirole are used in Parkinson’s treatment. This complete literature search was done using Google Scholar and PubMed. This review is to compare the safety and efficacy of ropinirole with that of Levodopa.
罗匹尼罗与左旋多巴:帕金森病的临床疗效更好
帕金森病是一种进行性的锥体外神经系统退行性疾病,影响骨骼肌系统的活动和控制。尽管帕金森病可以在任何年龄发生,但最常见于老年人,发病高峰年龄在60岁左右。左旋多巴和多巴胺激动剂如罗匹尼罗用于帕金森病的治疗。这个完整的文献检索是使用Google Scholar和PubMed完成的。本综述比较了罗匹尼罗与左旋多巴的安全性和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信